NASDAQ:TNDM - Tandem Diabetes Care Stock Price, Forecast & News

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Tandem Diabetes Care's stock reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care Inc (NASDAQ:TNDM) announced its earnings results on Tuesday, April, 30th. The medical device company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.10. The medical device company earned $66 million during the quarter, compared to the consensus estimate of $47.55 million. Tandem Diabetes Care had a negative net margin of 7.19% and a negative return on equity of 9.44%. The business's quarterly revenue was up 141.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.82) earnings per share. View Tandem Diabetes Care's Earnings History.

Tandem Diabetes Care is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Tandem Diabetes Care.

Tandem Diabetes Care will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

14 brokerages have issued twelve-month price objectives for Tandem Diabetes Care's shares. Their forecasts range from $65.00 to $100.00. On average, they anticipate Tandem Diabetes Care's share price to reach $79.79 in the next twelve months. This suggests that the stock has a possible downside of 10.9%. View Analyst Price Targets for Tandem Diabetes Care.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care.

News headlines about TNDM stock have been trending extremely negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Tandem Diabetes Care earned a news impact score of -4.1 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the immediate future. View News Stories for Tandem Diabetes Care.

Tandem Diabetes Care saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 6,970,000 shares, an increase of 17.7% from the December 31st total of 5,920,000 shares. Based on an average trading volume of 1,460,000 shares, the short-interest ratio is presently 4.8 days. Approximately 12.5% of the shares of the stock are sold short. View Tandem Diabetes Care's Current Options Chain.

Some companies that are related to Tandem Diabetes Care include Teleflex (TFX), Insulet (PODD), Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), ICU Medical (ICUI), Nevro (NVRO), NuVasive (NUVA), Cantel Medical (CMD), Glaukos (GKOS) and Irhythm Technologies (IRTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA) and Paypal (PYPL).

Tandem Diabetes Care's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (3.97%), Fred Alger Management LLC (2.43%), State Street Corp (2.26%), Delphi Management Partners VIII L.L.C. (1.69%), Eagle Asset Management Inc. (1.67%) and Goldman Sachs Group Inc. (1.27%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View Institutional Ownership Trends for Tandem Diabetes Care.

TNDM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Lord Abbett & CO. LLC, Fred Alger Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Marshall Wace North America L.P., Driehaus Capital Management LLC and Columbus Circle Investors. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller and Susan Morrison. View Insider Buying and Selling for Tandem Diabetes Care.

TNDM stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Delphi Management Partners VIII L.L.C., Jennison Associates LLC, Perceptive Advisors LLC, UBS Asset Management Americas Inc., J. Goldman & Co LP, Parkman Healthcare Partners LLC and Goldman Sachs Group Inc.. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Dick Allen and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care.

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TNDM stock can currently be purchased for approximately $89.54.

Tandem Diabetes Care has a market capitalization of $5.29 billion and generates $183.87 million in revenue each year. The medical device company earns $-122,610,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Tandem Diabetes Care employs 653 workers across the globe.View Additional Information About Tandem Diabetes Care.

The official website for Tandem Diabetes Care is http://www.tandemdiabetes.com/.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]